Insmed (NASDAQ:INSM) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Insmed (NASDAQ:INSM) in a research note published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $228.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on INSM. HC Wainwright restated a “buy” rating and issued a $230.00 price objective on shares of Insmed in a report on Monday, February 23rd. Barclays initiated coverage on shares of Insmed in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 target price on the stock. Royal Bank Of Canada boosted their price target on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group upped their price target on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Bank of America set a $203.00 price objective on Insmed in a research note on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $205.57.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $142.70 on Monday. The stock has a market cap of $30.76 billion, a price-to-earnings ratio of -22.26 and a beta of 1.13. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The stock’s 50-day moving average is $153.28 and its 200 day moving average is $166.11.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the previous year, the firm earned ($1.32) EPS. The business’s quarterly revenue was up 152.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the sale, the insider owned 41,754 shares of the company’s stock, valued at $7,315,300.80. This trade represents a 67.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 178,952 shares of company stock worth $29,998,133. 3.00% of the stock is owned by insiders.

Institutional Trading of Insmed

Institutional investors have recently modified their holdings of the company. Norges Bank purchased a new position in Insmed during the 4th quarter valued at about $506,625,000. Vanguard Group Inc. lifted its holdings in Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares during the period. RTW Investments LP grew its position in shares of Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after buying an additional 1,758,321 shares during the last quarter. Artisan Partners Limited Partnership grew its position in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after buying an additional 1,623,342 shares during the last quarter. Finally, Orbis Allan Gray Ltd purchased a new position in shares of Insmed during the second quarter valued at approximately $153,389,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.